GlassScriptPhysician profile
Paulo Acosta
NPI 1710097761
$1,365.08
in general payments reported to CMS, 2019-2025
22 companies · $235 in 2025
The $235 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.37 · 2020: $61.80 · 2021: $40.44 · 2023: $229 · 2024: $751 · 2025: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,215.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $260.23 | 2019-2025 | Nayzilam, Briviact, Fintepla |
| Genentech USA, INC. | $136.81 | 2024-2025 | Ocrevus, Ocrevus Zunovo |
| Neurelis, INC. | $131.24 | 2023-2025 | Valtoco |
| Alexion Pharmaceuticals, INC. | $130.54 | 2021-2024 | Ultomiris |
| Sk Life Science, INC. | $90.89 | 2021-2025 | |
| Acadia Pharmaceuticals INC | $89.44 | 2024 | Nuplazid |
| Neurocrine Biosciences, INC. | $61.22 | 2025 | |
| Pfizer INC. | $57.41 | 2023-2024 | |
| Amgen INC. | $55.61 | 2019-2024 | Uplizna |
| Lundbeck LLC | $53.67 | 2023-2024 | Vyepti |
| Takeda Pharmaceuticals U.S.A., INC. | $53.60 | 2023 | Gammagard |
| Catalyst Pharmaceuticals, INC. | $31.45 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $30.80 | 2025 | Austedo Xr |
| Biogen, INC. | $28.88 | 2023 | Vumerity, Avonex, Tysabri |
| Amneal Pharmaceuticals LLC | $25.61 | 2024 | Crexont |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $22.72 | 2023 | Uplizna |
| Medtronic, INC. | $20.93 | 2024 | Percept PC Brainsense |
| Emd Serono, INC. | $20.59 | 2020 | |
| Lilly USA, LLC | $19.28 | 2024 | Emgality |
| Eisai INC. | $16.51 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $15.06 | 2024 | Nuedexta |
| Zyla Life Sciences, INC. | $12.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paulo Acosta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.